Literature DB >> 11691746

Prophylactic treatment of anthrax with antibiotics.

C A Hart, N J Beeching.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11691746      PMCID： PMC1121531          DOI： 10.1136/bmj.323.7320.1017

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

Review 1.  Fluoroquinolone-induced tendinopathy: what do we know?

Authors:  R M Harrell
Journal:  South Med J       Date:  1999-06       Impact factor: 0.954

2.  Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment.

Authors:  M E Jones; N M Boenink; J Verhoef; K Köhrer; F J Schmitz
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

3.  Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora.

Authors:  P Richard; M H Delangle; F Raffi; E Espaze; H Richet
Journal:  Clin Infect Dis       Date:  2000-12-11       Impact factor: 9.079

4.  bmr3, a third multidrug transporter gene of Bacillus subtilis.

Authors:  R Ohki; M Murata
Journal:  J Bacteriol       Date:  1997-02       Impact factor: 3.490

Review 5.  Fluoroquinolones in paediatrics.

Authors:  H S Jafri; G H McCracken
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.

Authors:  F Guerin; E Varon; A B Hoï; L Gutmann; I Podglajen
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

Review 7.  Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors:  T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A M Friedlander; J Hauer; J McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  1999-05-12       Impact factor: 56.272

8.  Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.

Authors:  M J Ferrándiz; A Fenoll; J Liñares; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis.

Authors:  N Høiby; J O Jarløv; M Kemp; M Tvede; J M Bangsborg; A Kjerulf; C Pers; H Hansen
Journal:  Lancet       Date:  1997-01-18       Impact factor: 79.321

10.  Adverse drug reactions with fluoroquinolones.

Authors:  R J Royer
Journal:  Therapie       Date:  1996 Jul-Aug       Impact factor: 2.070
View more
  4 in total

1.  Response to bioterrorism. Terror weapons are regarded as weapons of mass destruction.

Authors:  Meng-Kin Lim
Journal:  BMJ       Date:  2002-02-09

Review 2.  Biological warfare and bioterrorism.

Authors:  Nicholas J Beeching; David A B Dance; Alastair R O Miller; Robert C Spencer
Journal:  BMJ       Date:  2002-02-09

Review 3.  Passive antibody administration (immediate immunity) as a specific defense against biological weapons.

Authors:  Arturo Casadevall
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

4.  Injectional anthrax at a Scottish district general hospital.

Authors:  D J Inverarity; V M Forrester; J G R Cumming; P J Paterson; R J Campbell; T J G Brooks; G L Carson; J P Ruddy
Journal:  Epidemiol Infect       Date:  2014-07-31       Impact factor: 4.434
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.